The ABCs of Lipoprotein(a): What Researchers and Practitioners Need to Know

Follow along as Dr. Koschinsky breaks down lipoprotein(a) and discusses its causal risk association with cardiovascular disease.
00:00 - 1:11 Welcome
01:13 - 02:43 Speaker Introduction
02:46 - 03:02 Disclaimer
03:05 - 03:07 Disclosures
03:11 - 03:56 Learning Objectives
03:45 - 04:23 Scientific Statement
04:25 - 13:05 Part 1: Structure of Lp(a) and Determination of Lp(a) Levels
13:06 - 18:20 Part 2: Elevated Lp(a) and Risk for Cardiovascular Disease
18:20 - 21:46 Part 3: Biosynthesis and Catabolism of Lp(a)
21:46 - 37:52 Part 4: Pathogenic Mechanisms of Lp(a)
37:53 - 41:39 Part 5: Pharmacological Lowering of Lp(a)
41:39 - 45:53 Part 6: Use of Lp(a) in Clinical Practice
45:54 - 47:51 Key Messages
47:52 - 58:48 Q & A
58:50 - 59:34 Closing

[@susanbeever5708]

Has anyone investigated how oxcarbazepine that up-regulates TRPV1 and TRPV4 also increases Lp(a) in children after 1 year of oxcarbazepine treatment?

[@feridhosni8179]

Thank You very much !

[@triptideb570]

Excellent

[@feridhosni8179]

Hello Doctor !❤

[@feridhosni8179]

Instructor for Tunisia

[@philbo4433]

25 Seconds Left

[@adamgermaineexists]

Abcdefg

[@melvinbohon2039]

Are